ResearcherSecond Military Medical UniversityActive in the last 2 years

Xiaoyi Yin

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5136375299. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2026: 2 papers

Papers 2

Rewiring metabolic-immune circuitry in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1016/j.cpt.2026.05.001 ↗
ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. First author DOI 10.1016/j.isci.2026.117479 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gang Jin · 2 shared papers, 2026 · strength 0.90
- Paper Rewiring metabolic-immune circuitry in pancreatic ductal adenocarcinoma (PDAC). DOI 10.1016/j.cpt.2026.05.001 ↗
- Paper ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. DOI 10.1016/j.isci.2026.117479 ↗
Huan Wang · 1 shared paper, 2026 · strength 0.27
- Paper ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. DOI 10.1016/j.isci.2026.117479 ↗
Suizhi Gao · 1 shared paper, 2026 · strength 0.27
- Paper ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. DOI 10.1016/j.isci.2026.117479 ↗
Kailian Zheng · 1 shared paper, 2026 · strength 0.27
- Paper ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. DOI 10.1016/j.isci.2026.117479 ↗
Shiwei Guo · 1 shared paper, 2026 · strength 0.27
- Paper ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. DOI 10.1016/j.isci.2026.117479 ↗
Xiaohan Shi · 1 shared paper, 2026 · strength 0.27
- Paper ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. DOI 10.1016/j.isci.2026.117479 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.